5th Nov 2015 10:39
LONDON (Alliance News) - Proteome Sciences PLC Thursday said it received positive results from its recent study on Alzheimer's disease.
The life sciences company said the study showed that proprietary inhibitors of casein kinase 1 delta reduced the level of tau phosphorylation in a second in vivo model of Alzheimer's disease tauopathy.
Compounds were given orally for five days and the level of tau phosphorylation in the brain cortex was reduced compared to the control group. These results confirmed and are consistent with the previous in vivo study in a different Alzheimer's disease model that revealed reduced tau phosphorylation when the compounds were given daily for eight weeks, Proteome said.
"We now have compelling evidence that both acute and chronic dosing of our CK1d inhibitors is reducing levels of phosphorylated tau in the brains of two different models of AD. Surprisingly, the effect of acute dosing on phosphorylated tau was nearly as potent as the chronic administration," Chief Operating Officer Ian Pike said in a statement.
"Using our SysQuant global phosphoproteomic workflow we also saw that acute dosing resulted in some early changes in many of the downstream pathways we have previously identified that are affected by tau toxicity in human AD and were responsive to chronic CK1d inhibitor dosing," Pike said.
"The data from the two in-vivo studies provides excellent support for the beneficial effects of our compounds PS 110 and PS 278-05 and their translation to human disease and adds further substance to our partnering discussions," he added.
Shares in Proteome were trading up 5.2% at 18.28 pence Thursday morning.
By Karolina Kaminska; [email protected] @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Proteome